Low MiR-187 Expression Promotes Resistance to Chemoradiation Therapy In Vitro and Correlates with Treatment Failure in Patients with Esophageal Adenocarcinoma
Tóm tắt
Esophageal adenocarcinoma (EAC) has a poor prognosis and is increasing in incidence in many Western populations. Neoadjuvant chemoradiation therapy (CRT) followed by surgery is increasingly the standard of care for locally advanced EAC; however, resistance to treatment is a significant clinical problem. The identification of both novel biomarkers predicting response to treatment and novel therapeutic targets to enhance the efficacy of CRT is key to improving survival rates in EAC. In this study, we performed global microRNA (miRNA) profiling of pretreatment EAC biopsies and identified 67 miRNAs significantly altered in patients who are resistant to CRT. One of these miRNAs, miR-187, was significantly decreased in pretreatment EAC tumors from patients having a poor response to neoadjuvant CRT, highlighting downregulation of miR-187 as a potential mediator of treatment resistance in EAC. In vitro, miR-187 was demonstrated to play a functional role in modulating sensitivity to X-ray radiation and cisplatin in EAC and its dysregulation was demonstrated to be due to chromosomal alterations. In vitro, miR-187 altered expression of a diverse array of pathways, including the immune regulator complement component 3 (C3), serum levels of which we have previously demonstrated to predict patient response to CRT. In vivo, expression of C3 was significantly increased in tumors from patients having a poor response to CRT. This study highlights for the first time a role for miR-187 as a novel biomarker of response to CRT and a potential therapeutic target for enhancing the efficacy of CRT in EAC.
Tài liệu tham khảo
Arnold M, Soerjomataram I, Ferlay J, Forman D. (2015) Global incidence of oesophageal cancer by histological subtype in 2012. Gut. 64:381–7.
Pennathur A, Gibson MK, Jobe BA, Luketich JD. (2013) Oesophageal carcinoma. Lancet. 381:400–12.
Thrift AP, Whiteman DC. (2012) The incidence of esophageal adenocarcinoma continues to rise: Analysis of period and birth cohort effects on recent trends. Ann. Oncol. 23:3155–62.
Murphy TJ, Ravi N, Reynolds JV. (2008) Treatment options for esophageal cancer. Expert Opin. Pharmacother. 9:3197–210.
Reynolds JV, et al. (2007) Long-term outcomes following neoadjuvant chemoradiotherapy for esophageal cancer. Ann. Surg. 245:707–16.
van Hagen P, et al. (2012) Preoperative chemora-diotherapy for esophageal or junctional cancer. N. Engl. J. Med. 366:2074–84.
Geh JI, Crellin AM, Glynne-Jones R. (2001) Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancer. Br. J. Surg. 88:338–56.
Lynam-Lennon N, Maher SG, Reynolds JV. (2009) The roles of microRNA in cancer and apoptosis. Biol. Rev. Camb. Philos. Soc. 84:55–71.
Orellana EA, Kasinski AL. (2015) MicroRNAs in cancer: A historical perspective on the path from discovery to therapy. Cancers (Basel). 7:1388–405.
Lu J, et al. (2005) MicroRNA expression profiles classify human cancers. Nature. 435:834–8.
Sakai NS, Samia-Aly E, Barbera M, Fitzgerald RC. (2013) A review of the current understanding and clinical utility of miRNAs in esophageal cancer. Semin. Cancer Biol. 23:512–21.
Skinner HD, et al. (2014) A validated miRNA profile predicts response to therapy in esophageal adenocarcinoma. Cancer. 120:3635–41.
Lynam-Lennon N, et al. (2012) MicroRNA-31 modulates tumour sensitivity to radiation in oesophageal adenocarcinoma. J. Mol. Med. (Berl). 90:1449–58.
Bibby BA, Reynolds JV, Maher SG. (2015) MicroRNA-330-5p as a putative modulator of neoadjuvant chemoradiotherapy sensitivity in oesophageal adenocarcinoma. PLoS One. 10:e0134180.
Maher SG, et al. (2009) Gene expression analysis of diagnostic biopsies predicts pathological response to neoadjuvant chemoradiotherapy of esophageal cancer. Ann. Surg. 250:729–37.
Mandard AM, et al. (1994) Pathologic assessment of tumor regression after preoperative chemoradiotherapy of esophageal carcinoma. Clinicopathologic correlations. Cancer. 73:2680–6.
Lynam-Lennon N, et al. (2010) Alterations in DNA repair efficiency are involved in the radioresistance of esophageal adenocarcinoma. Radiat. Res. 174:703–11.
Livak KJ, Schmittgen TD. (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods. 25:402–8.
Casanova-Salas I, et al. (2014) Identification of miR-187 and miR-182 as biomarkers of early diagnosis and prognosis in patients with prostate cancer treated with radical prostatectomy. J. Urol. 192:252–9.
Zhao J, et al. (2013) MicroRNA-187, down-regulated in clear cell renal cell carcinoma and associated with lower survival, inhibits cell growth and migration though targeting B7-H3. Biochem. Biophys. Res. Commun. 438:439–44.
Calin GA, et al. (2004) Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc. Natl. Acad. Sci. U. S. A. 101:2999–3004.
Maher SG, et al. (2011) Serum proteomic profiling reveals that pretreatment complement protein levels are predictive of esophageal cancer patient response to neoadjuvant chemoradiation. Ann. Surg. 254:809–16.
Wang L, et al. (2013) Lin28 mediates radiation resistance of breast cancer cells via regulation of caspase, H2A.X and Let-7 signaling. PLoS One. 8:e67373.
Liu B, et al. (2015) DICER-dependent biogenesis of let-7 miRNAs affects human cell response to DNA damage via targeting p21/p27. Nucleic Acids Res. 43:1626–36.
Zhang CZ, Leibowitz ML, Pellman D. (2013) Chromothripsis and beyond: Rapid genome evolution from complex chromosomal rearrangements. Genes. Dev. 27:2513–30.
Nones K, et al. (2014) Genomic catastrophes frequently arise in esophageal adenocarcinoma and drive tumorigenesis. Nat. Commun. 5:5224.
Barrett MT, Galipeau PC, Sanchez CA, Emond MJ, Reid BJ. (1996) Determination of the frequency of loss of heterozygosity in esophageal adenocarcinoma by cell sorting, whole genome amplification and microsatellite polymorphisms. Oncogene. 12:1873–8.
Barrett MT, Schutte M, Kern SE, Reid BJ. (1996) Allelic loss and mutational analysis of the DPC4 gene in esophageal adenocarcinoma. Cancer Res. 56:4351–3.
Kim YW, et al. (2014) Differential microRNA expression signatures and cell type-specific association with Taxol resistance in ovarian cancer cells. Drug Des. Devel. Ther. 8:293–314.
Mulrane L, et al. (2012) miR-187 is an independent prognostic factor in breast cancer and confers increased invasive potential in vitro. Clin. Cancer Res. 18:6702–13.
Chao A, et al. (2012) Regulation of ovarian cancer progression by microRNA-187 through targeting Disabled homolog-2. Oncogene. 31:764–75.
Maziere P, Enright AJ. (2007) Prediction of microRNA targets. Drug Discov. Today. 12:452–8.
Zhao L, Bode AM, Cao Y, Dong Z. (2012) Regulatory mechanisms and clinical perspectives of miRNA in tumor radiosensitivity. Carcinogenesis. 33:2220–7.
Lin CC, et al. (2011) A KLF4-miRNA-206 autoregulatory feedback loop can promote or inhibit protein translation depending upon cell context. Mol. Cell. Biol. 31:2513–27.
Vasudevan S. (2012) Posttranscriptional upregulation by microRNAs. Wiley Interdiscip. Rev. RNA. 3:311–30.
Rentoft M, et al. (2014) Expression of CXCL10 is associated with response to radiotherapy and overall survival in squamous cell carcinoma of the tongue. Tumour Biol. 35:4191–8.
Li C, et al. (2014) CXCL10 mRNA expression predicts response to neoadjuvant chemoradiotherapy in rectal cancer patients. Tumour Biol. 35:9683–91.
Yang LL, Wang BQ, Chen LL, Luo HQ, Wu JB. (2012) CXCL10 enhances radiotherapy effects in HeLa cells through cell cycle redistribution. Oncol. Lett. 3:383–6.
Galindo-Moreno J, et al. (2014) Apolipoprotein L2 contains a BH3-like domain but it does not behave as a BH3-only protein. Cell Death Dis. 5:e1275.
Zhaorigetu S, Yang Z, Toma I, McCaffrey TA, Hu CA. (2011) Apolipoprotein L6, induced in atherosclerotic lesions, promotes apoptosis and blocks Beclin 1-dependent autophagy in atherosclerotic cells. J. Biol. Chem. 286:27389–98.
Zhaorigetu S, Wan G, Kaini R, Jiang Z, Hu CA. (2008) ApoL1, a BH3-only lipid-binding protein, induces autophagic cell death. Autophagy. 4:1079–82.
Weichselbaum RR, et al. (2008) An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer. Proc. Natl. Acad. Sci. U. S. A. 105:18490–5.
Pio R, Ajona D, Lambris JD. (2013) Complement inhibition in cancer therapy. Semin. Immunol. 25:54–64.
Dunkelberger JR, Song WC. (2010) Complement and its role in innate and adaptive immune responses. Cell Res. 20:34–50.
Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. (2009) Cancer-related inflammation, the seventh hallmark of cancer: Links to genetic instability. Carcinogenesis. 30:1073–81.
Multhoff G, Radons J. (2012) Radiation, inflammation, and immune responses in cancer. Front. Oncol. 2:58.
Elvington M, et al. (2014) Complement-dependent modulation of antitumor immunity following radiation therapy. Cell Rep. 8:818–30.